Alzinova AB · OMXSTO:ALZ

Alzinova AB — Investor Presentation (October 2024)

32 slides from Alzinova AB's investor presentation, Oct 2, 2024

  1. Slide 1: Alzinova Company presentation October 2024

    We will make it possible for Alzheimer's patients Alzinova to live an independent and active life Company presentation | October | 2024 ©2024 Alzinova AB (publ), All rights reserved

  2. Slide 2: Forward looking statements

    Forward looking statements This information contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strate

  3. Slide 3: Imagine if there was a vaccine against Alzheimer's disease

    Imagine if there was a vaccine against Alzheimer's disease ©2024 Alzinova AB (publ), All rights reserved

  4. Slide 4: Alzinova is developing the first specific vaccine against Alzheimer's disease

    Swedish biopharma company | Based in Gothenburg Founded 2011 Alzinova is High unmet medical need for Alzheimer’s disease developing the – huge market opportunity first specific Innovative science & proprietary technology enables vaccine against development of disease-modifying treatments for Alzheim

  5. Slide 5: Alzheimer's disease

    Alzheimer’s disease • Slowly progressing disease • Caused by toxic formations in the brain called oligomers – consists of Aβ-42 peptide • Destroys brain structures Memory Delusions Loss of loss, & poor Depression Agitation independent Cause of confusion judgement life death • Need for targeted treat

  6. Slide 6: Alzheimer's disease – huge unmet medical need

    Alzheimer’s disease – huge unmet medical need Dementia >55 million people suffer from dementia Impacts quality US $1.3 trillion >150 million people in 2050 of life (US $2.8 trillion by Patients, 2030) families, Annual cost care givers 60-70% are Alzheimer’s patients World Alzheimer’s Report 2015, 20

  7. Slide 7: Unmet medical need

    Cognitive and physical decline, leads to increased Individual dependency on caregiving and later full-time care. Unpaid family and friend caregivers can experience Caregiver physical, financial & emotional strains. Unmet Elderly care requires institutionalized housing, managing medical need Hospital

  8. Slide 8: >100 million people will suffer from Alzheimer's in 2050

    >100 million people will suffer from Alzheimer’s in 2050 ©2024 Alzinova AB (publ), All rights reserved

  9. Slide 9: Enormous market potential

    Enormous market potential Alzheimer’s therapeutics market > US $13 billion by 2028 Substantia l market 2 out of 7 predicted blockbusters by 2026 are new anti-Alzheimer’s potential drugs with US $1.7 - 4.5 billion projected annual revenue for Alzinova Market growth driven by introduction of novel the

  10. Slide 10: Potential breakthrough in Alzheimer's

    Potential breakthrough in Alzheimer’s High unmet medical & market potential for disease-modifying treatments of Alzheimer’s disease ✓ Short-term goal: ✓ Mid-term goal: ✓ Long-term goal: ✓ First clinical trial targeting oligomers ➢ ALZ-101 Initiate Phase 2 in 2024 ➢ Bring to market in partnership wit

  11. Slide 11: Alzinova's business model – develop, document, prepare, partner & bring to market

    Develop breakthrough disease-modifying treatments based on proprietary AβCC technology Document safety and tolerability in patients with Alzheimer’s Alzinova’s disease business model – develop, document, Prepare (in parallel) for phase 2 to optimize the candidates value prepare, partner & bring to m

  12. Slide 12: Our candidates for treating Alzheimer's disease

    Our candidates for treating Alzheimer’s disease ©2024 Alzinova AB (publ), All rights reserved

  13. Slide 13: AβCC peptide technology targets the toxic oligomers

    Alzinova’s AβCC peptide technology enables high precision, with antibodies specifically targeting the toxic oligomers Aβ – amyloid-beta ©2024 Alzinova AB (publ), All rights reserved

  14. Slide 14: Two differentiated, oligomer-specific products based on the same technology

    Two differentiated, oligomer- specific products based on the same proprietary technology • Highly specific disease modifying treatments, directed towards the toxic accumulations of amyloid beta in the brain • Opportunity to become effective and well tolerated treatments to halt and prevent Alzheimer

  15. Slide 15: ALZ-101 represent a potential breakthrough in treating Alzheimer's Disease

    ALZ-101 represent a potential breakthrough in treating Alzheimer's Disease • The body generates specific antibodies against toxic oligomers ALZ-101 vaccine • High patient compliance (few booster doses) • Long-acting • Preventive treatment possible • Large potential patient population ©2024 Alzinova

  16. Slide 16: ALZ-201 a complement to the vaccine ALZ-101

    ALZ-201 a complement to the vaccine ALZ-101 in treating Alzheimer's Disease • Unique binding profile for targeting toxic oligomers ALZ-201 monoclonal antibody • Several potential uses for the antibody: − complement to the vaccine ALZ-101 for patients who, for various reasons, need higher levels of a

  17. Slide 17: Improving quality of care – for more patients

    Improving quality of care – for more patients X1 X 50 Based on Swedish healthcare system, and that the two treatments have equivalent clinical efficacy, total treatment duration and drug cost. Sources: SCB Statistics Sweden, Swedish regional healthcare cost ©2024 Alzinova AB (publ), All rights reser

  18. Slide 18: Alzinova's product pipeline offers complementary ways to fight Alzheimer's Disease

    Alzinova's product pipeline offers complementary ways to fight Alzheimer’s Disease Candidates Discovery Pre-clinical Clinical NDA/MAA Next Major Milestone ALZ-1011) therapeutic Positive results Q1 2024, Initiate part A2 – vaccine from part A - Jan optimisation of dose for phase 2 2024 ALZ-2012) mono

  19. Slide 19: What if there was a vaccine for Alzheimer's?

    What if there was a vaccine for Alzheimer's? Alzinova Other actors Targeted treatment – oligomer specific Target plaques Vaccine Non-specific treatments Antibody - as a complement to the vaccine Often complicated drug Fast, effective and uncomplicated treatments Likelihood for good efficacy Unlikely

  20. Slide 20: ALZ-101 – favourable profile with best-in-class opportunity

    ALZ-101 – favourable profile with “best-in-class” opportunity ALZ-101 Donanemab Lecanemab Companies Alzinova Eli Lilly BioArctic/Eisai/Biogen Primary target Aβ oligomers plaque (P-Glu3-Aβ) Aβ monomers/fibrils/oligomers –> good efficacy +++ (potential) + + Compliance +++ + + Low cost* +++ ++ + Low so

  21. Slide 21: Alzinova's ALZ-101 Phase 1b-study

    Alzinova’s ALZ-101 Phase 1b-study ©2024 Alzinova AB (publ), All rights reserved

  22. Slide 22: ALZ-101 phase 1b clinical study in patients with Alzheimer's disease

    ALZ-101 phase 1b clinical study in patients with Alzheimer’s disease Study: Double-blind, randomized, placebo-controlled study on safety, tolerability and immunogenicity. Part A – ALZ-101 (125 and 250 μg) or placebo, given at weeks 0, 4, 8 and 16, if not eligible for Part B, follow-up for additional

  23. Slide 23: Strong data in phase 1b study

    Strong data in phase 1b study - Favourable safety and tolerability outcome Top-line results – part A1 - Favourable safety and tolerability; 16 weeks treatment - High immune responder rate - Antibody levels increasing with the number of doses given Full analysis confirms top-line results – part A1 -

  24. Slide 24: Phase 2 preparations

    Phase 2 preparations Interactions with Regulatory Authorities – FDA and EMA - Positive feedback regarding ongoing clinical phase - Fast track application based on phase 1b data Comprehensive preparation work - Scalable manufacturing process - Study design and protocol development - CRO and site sele

  25. Slide 25: Corporate & Finance

    Corporate & Finance ©2024 Alzinova AB (publ), All rights reserved

  26. Slide 26: Experienced management team

    Experienced management team Tord Labuda, M.Sci., PhD Anders Sandberg, PhD Erik Kullgren Chief Executive Officer Chief Scientific Officer Interim Chief Financial Officer >15 years experience from senior Co-Founder >25 years experience within positions in medicine, clinical- and >20 years experience i

  27. Slide 27: Board of Directors with extensive pharma and biopharma experience

    Board of Directors with extensive pharma and Julian Aleksov Anders Blom Per-Göran Gillberg, PhD biopharma Chairman Member Member experience >25 years experience in finance and international development >25 years experience in international finance and business 35 years experience in drug development

  28. Slide 28: Capitalization table, summary of shares and options

    Capitalization table, summary of shares and options Shareholders, as per 28 June 2024: Name No. of shares Capital, % Maida Vale Capital AB 6,748,920 15.16% Försäkrings AB Avanza Pension 3,038,512 6.82% Nordnet Pensionsförsäkring AB 1,358,232 3.05% Patrik Ahlvin 1,004,750 2.26% Market cap Sara Gjertz

  29. Slide 29: Financial information – Key figures, Jan-June 2024

    Financial information Key figures, for Jan-June 2024 (Jan-June 2023) Total balance sheet Cash balance Cashflow Result Equity ratio 112 5 -10 -17 93% (127) (37) (5) (96%) (3) MSEK MSEK MSEK MSEK • Mainly invested in capitalized costs for R&D, focus on present ALZ-101 phase 1 study and preparing ALZ-1

  30. Slide 30: Product pipeline and value inflection points

    Product pipeline and value inflection points Discovery Pre-clinical Clinical phase NDA/MAA Phase 1b – Strategic ALZ-101 Phase 1b – Part A1 Phase 2 – 2024+ Phase 3 partnerships Part A2 Phase 1b – Part B ALZ-201 Phase 1 Portfolio enhancemen ts New innovative discovery projects ©2024 Alzinova AB (publ)

  31. Slide 31: Investment highlights

    Investment highlights Alzinova’s promising candidates address vast unmet medical needs with potential for significant societal costs reductions compared with current treatments Data show that the unique specificity of Alzinova’s vaccine (ALZ-101) and the monoclonal antibody (ALZ-201) provides “best-

  32. Slide 32: Alzinova

    CEO Tord Labuda Alzinova Email: tord.labuda@alzinova.com Phone: +46 70-838 23 23 www.alzinova.com https://www.linkedin.com/company/alzinova-ab/ ©2024 Alzinova AB (publ), All rights reserved

Alzinova — Investor Presentation (October 2024) on 6ix